by nhcoa_media | Feb 29, 2024 | Blog
With nearly four years behind us since the COVID-19 pandemic began, it’s easy to feel lost and confused about the vaccination process. There are different formulas created by different pharmaceutical companies, and trails of updated boosters that follow each of them....
by nhcoa_media | Jan 26, 2024 | Blog
La subvariante JN.1, derivada de la variante BA.2.86, es la más reciente variante desarrollada del virus de COVID-19. Apareció por primera vez en estudios realizados en México y se identificó en paralelo en Luxemburgo y Estados Unidos a finales de agosto de 2023....
by nhcoa_media | Jan 26, 2024 | Blog
JN.1 is the most recently developed variant of the COVID-19 virus, and it is currently the most widely circulating variant. It is derived from the BA.2.86 variant, another Omicron subvariant. JN.1 was first discovered in Luxembourg and the United States, in late...
by nhcoa_media | Dec 20, 2023 | Blog
La Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) aprobó recientemente varios medicamentos antivirales para tratar el COVID-19, incluyendo el medicamento antiviral Veklury (Remdesivir) para adultos y ciertos pacientes...
by nhcoa_media | Dec 20, 2023 | Blog
Recently, the US Food and Drug Administration (FDA) approved new antiviral drugs for the treatment of the COVID-19 virus. Veklury (Remdesivir) is an antiviral drug meant for adults and certain pediatric patients infected with COVID-19, and is administered...
Recent Comments